Istari
Actually I think that the preclinical (rat based) result on heart muscle treatment de risks the stock a lot more that the release of the MK Elisa test (or any other hopeful test) to researchers for further analysis.
The market knows not what it sees IMO. A key question is whether some of the bigger players will pick up on it .
http://www.biotechnologynews.net/storyview.asp?storyid=2390085
cheers
la jolla, page-23
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1499234 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 381703 | 2 |
View Market Depth
| Last trade - 10.00am 12/07/2024 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable